New NHL Drug Hits UK Market   Leave a comment

NappUK-based Napp Pharmaceuticals released a new cancer fighting product this week. This chemotherapy agent is called Levact and is based on the natural anticancer properties of mustard seed, according to Pharma Times. Levact is being specifically marketed for non-Hodgkin’s lymphoma patients. During clinical trials, the response rate was “77% in one study, 75% in another.” To read more about this new drug, click here.

There are two drawbacks to this new breakthrough, however. Pharma Times claims that the drug is intended only for patients with low-grade NHL, and not advanced. Secondly, Levact is only available in the UK, at least for now.


Posted September 21, 2010 by lymphomactivist in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: